Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

NCT07627711 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)
Unresectable Locally Advanced
Metastatic Disease

Interventions

BIOLOGICAL: EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)
BIOLOGICAL: EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1)
DRUG: Lymphodepleting chemotherapy (Flu/Cy)

Sponsor

Beijing Biotech